HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Failure of carbazochrome sodium sulfonate (AC-17) to prevent dengue vascular permeability or shock: a randomized, controlled trial.

AbstractOBJECTIVE:
We studied the ability of carbazochrome sodium sulfonate (AC-17) to prevent capillary permeability in dengue hemorrhagic fever/dengue shock syndrome.
METHOD:
A randomized, placebo-controlled trial in 95 children stratified by age and sex was conducted in two hospitals during 1992. AC-17 (n = 45 cases) or B vitamins as placebo (n = 50) were given as a bolus infusion and then as a continuous drip for 24 hours; a total of 300 mg of AC-17 was administered on the first 2 days and 150 mg on the third day.
RESULTS:
The two groups were comparable in age, sex, duration of illness, and clinical manifestations. No significant difference in shock or pleural effusion was noted between the two groups. Shock developed in 8.9% (4/45) of patients in the AC-17 group and 6% (3/50) in the placebo group (p = 0.44). Pleural effusion was found at 0, 24, 48, and 72 hours after admission in 4.4%, 20%, 31.1%, and 20% in the AC-17 group and 2%, 14%, 28%, and 14% in the placebo group, respectively.
CONCLUSION:
Administration of AC-17 does not prevent plasma leakage or shock in dengue hemorrhagic fever/dengue shock syndrome.
AuthorsS Tassniyom, S Vasanawathana, T Dhiensiri, A Nisalak, A Chirawatkul
JournalThe Journal of pediatrics (J Pediatr) Vol. 131 Issue 4 Pg. 525-8 (Oct 1997) ISSN: 0022-3476 [Print] United States
PMID9386652 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Hemostatics
  • Adrenochrome
  • carbazochrome
Topics
  • Adrenochrome (analogs & derivatives, pharmacology, therapeutic use)
  • Capillary Permeability (drug effects)
  • Child
  • Child, Preschool
  • Female
  • Hemostatics (pharmacology, therapeutic use)
  • Hospitalization
  • Humans
  • Infant
  • Infant, Newborn
  • Length of Stay
  • Male
  • Severe Dengue (diagnosis, drug therapy, rehabilitation)
  • Treatment Failure

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: